Health and Fitness Health and Fitness
Thu, April 25, 2013
Wed, April 24, 2013
Tue, April 23, 2013
Mon, April 22, 2013
Sun, April 21, 2013
Fri, April 19, 2013
Thu, April 18, 2013
Wed, April 17, 2013
Tue, April 16, 2013
Mon, April 15, 2013
Fri, April 12, 2013
Thu, April 11, 2013
[ Thu, Apr 11th 2013 ] - Market Wire
15 PM EDT
Wed, April 10, 2013
Tue, April 9, 2013
[ Tue, Apr 09th 2013 ] - Market Wire
30 a.m. ET
Mon, April 8, 2013
Sat, April 6, 2013
Fri, April 5, 2013
Thu, April 4, 2013
Wed, April 3, 2013
Tue, April 2, 2013
Mon, April 1, 2013
Fri, March 29, 2013

Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013


//health-fitness.news-articles.net/content/2013/ .. t-conference-call-and-webcast-on-may-3-2013.html
Published in Health and Fitness on Thursday, April 11th 2013 at 13:16 GMT by Market Wire   Print publication without navigation


Regeneron to Report First Quarter 2013 Financial and Operating Results and Host... -- TARRYTOWN, N.Y., April 11, 2013 /PRNewswire/ --

TARRYTOWN, N.Y., April 11, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)today announced that it will report its first quarter 2013 financial and operating results on Friday, May 3, 2013, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information   
To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International).  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at [ www.regeneron.com ].  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days. 

About Regeneron Pharmaceuticals, Inc.   
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.  For additional information about the company, please visit [ www.regeneron.com ].

Contact Information:




Michael Aberman, M.D.     

Peter Dworkin

Investor Relations     

Corporate Communications                               

914-847-7799  

914.847.7640                

[ michael.aberman@regeneron.com ]   

[ peter.dworkin@regeneron.com ]

SOURCE Regeneron Pharmaceuticals, Inc.



RELATED LINKS
[ http://www.regeneron.com ]

Publication Contributing Sources